biotech / news / / The Manila Times
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussions.Strong industry reputation and commercial track record in high-value pharmaceutical markets including oncology and ophthalmology.
NovaBridge appointed Mark Hagler, ex-Sun Pharma CCO, as President and Chief Commercial Officer.
KEY POINTS
- Givastomig showed positive topline results in Phase 1b for first-line gastric cancer.
- VIS-101 completed a Phase 2a study for wet AMD and Phase 2b is planned for H2 2026.
- NovaBridge owns worldwide rights outside China to uliledlimab, targeting adenosine-driven immunosuppression in cancer.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →